Cost-minimization analysis of piperacillin/tazobactam versus imipenem/cilastatin for the treatment of serious infections: A Canadian hospital perspective

Annals of Pharmacotherapy

Volumn 33, Issue 2, 1999, Pages 156-162

  Marra, Fawziah O ^a   Frighetto, Luciana O ^c   Marra, Carlo A ^c   Sleigh, Kenna M ^c   Stiver, H Grant ^c   Bryce, Elizabeth A ^c   Reynolds, Robert P ^c   Jewesson, Peter J ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Clinical Services Unit Pharmaceutical Sciences Vancouver Acute Canada   (Canada)

^c NONE

Author keywords

Cost effectiveness; Imipenem cilastatin; Piperacillin tazobactam

Indexed keywords

CILASTATIN PLUS IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; HOSPITALIZATION; HUMAN; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE;

ADULT; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; BRITISH COLUMBIA; CILASTATIN; COSTS AND COST ANALYSIS; DECISION TREES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ECONOMICS, PHARMACEUTICAL; ENZYME INHIBITORS; FEMALE; HUMANS; IMIPENEM; MALE; MODELS, ECONOMIC; PENICILLANIC ACID; PENICILLINS; PIPERACILLIN; PROSPECTIVE STUDIES; PROTEASE INHIBITORS; STATISTICS, NONPARAMETRIC; THIENAMYCINS; TREATMENT OUTCOME;

EID: 0033011936     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.17366     Document Type: Article

References (21)

1. Birnbaum J, Kahan FM, Kropp H, MacDonald JS, Carbapenems, a new class of beta-lactam antibiotic. Am J Med 1985;78(suppl 6A):3-21.
2. Balfour JA, Bryson HM, Brogden RN. Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections. Drugs 1996;51:99-136.
3. Bryson HM, Brogden RN. Piperacillin/tazobactam: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1994;47:506-35.
4. Jacobus NV, Immermann FW, Gupte JM, Testa RT. Susceptibility of anaerobes in Phase 3 clinical studies of piperacillin/tazobactam. Clin Infect Dis 1993;16(suppl 4):344-8.
5. Jones RN, Pfaller MA, Fuchs PC, Aldndge K, Allen SD, Gerlach EH. Piperacillin/tazobactam (YTR 830) combination: comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains, Diagn Microbiol Infect Dis 1989;12:494-8.
6. Eliopoulos GM, Klimm K, Ferraro MJ, Jacoby GA, Moellering RC. Comparative in vitro activity of piperacillin combined with beta-lactamase inhibitor tazobactam (YTR 830). Diagn Microbiol Infect Dis 1989; 12:481-8.
7. Fass RJ, Prior RB. Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate. Antimicrob Agents Chemother 1989; 33:1268-74.
8. Jhee SS, Gill MA, Yellin AE, Berne TV, Heseltine PN, Appleman MD. Pharmacoeconomics of piperacillin/tazobactam and imipenem/cilastatin in the treatment of patients with intra-abdominal infections. Clin Ther 1995;17:126-35.
9. Niinikoski J, Havia T, Alhava E, Paakkonen M, Miettinen P, Kivilaakso E, et al. Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections. Surg Gynecol Obstet 1993;176:255-61.
10. Brismar B, Malmborg AS, Tunevall G, Wretlind B, Bergman L, Mentzing LO, et al. Piperacillin/tazobactam versus imipenen/cilastatin for the treatment of intra-abdominal infections. Antimicrob Agents Chemother 1992;36:2766-73.
11. Jaccard C, Troillet N, Habarth S, Zanetti G, Aymon D, Schneider R, et al. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998;42:2966-72.
12. Marra F, Reynolds R, Stiver G, Bryce E, Sleigh K, Frighetto L, et al. Piperacillin/tazobactam versus imipenem/cilastatin: a double-blind, randomized formulary feasibility study at a major teaching hospital. Diagn Microbiol Infect Dis 1998;30:355-68.
13. Hallas J, Harvald B, Gram LF, Grodum E, Brosen K, Haghfelt T, et al. Drug-related hospital admissions: the role of definitions and intensity of data collection and the possibility of prevention. J Intern Med 1990;228: 83-90.
14. McKinnon PS, Paladine JA, Grayson ML, Gibbons GW, Karchmer AW. Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis 1997;24:57-63.
15. Larson LN. Cost determination and analysis. In: Bootman JL, Townsend RJ, McGhan WF, eds. Principles of pharmacoeconomics. 2nd ed. Cincinnati, OH: Harvey Whitney Books Co., 1996:44-59.
16. Martinusen S, Chen D, Frighetto L, Bunz D, Stiver G, Jewesson P. A comparison of cefoxitin and ceftizoxime in a hospital therapeutic interchange program. Can Med Assoc J 1993;148:1161-9.
17. 1996 British Columbia Medical Association guide to fees. Vancouver, BC, Canada: Medical Association, 1997.
18. Rittenhouse BE. Designing and conducting cost-minimization and cost-effectiveness analyses. In: Spilker B, eds. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. New York: Lippincott Raven Publishers, 1996;1093-105.
19. Drummond MF, Menzin J, Oster G. Problems in undertaking pharmacoeconomic assessments in phase III clinical trials: the case of colony-stimulating factors. In: Spilker B. eds. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. New York: Lippincott Raven Publishers, 1996:1173-8.
20. Finkler SA. The distinction between costs and charges. Ann Intern Med 1982;96:102-9.
21. Osterhaus JT, Townsend RJ. Incorporating pharmacoeconomic research into clinical trials. In: Bootman JL, Townsend RJ, McGhan WF, eds. Principles of pharmacoeconomics. 2nd ed. Cincinnati, OH: Harvey Whitney Books Co., 1996:196-211.